Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: Updated analysis

Clinical Epidemiology

Volumn 2, Issue 1, 2010, Pages 29-36

  Kornum, Jette B ^a   Nielsen, Rikke B ^a   Pedersen, Lars ^a   Mortensen, Preben B ^b   Nørgaard, Mette ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Clinical database; Data validity; Medical complications; Stroke

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DENMARK; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HEART ATRIUM SEPTUM DEFECT; HEART SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYDRONEPHROSIS; INFANT; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL SMOKING; PARITY; PLAGIOCEPHALY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PREVALENCE; PULMONARY ARTERY STENOSIS; RISK FACTOR; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

EID: 77953391067     PISSN: None     EISSN: 11791349     Source Type: Book Series    
DOI: 10.2147/clep.s9256     Document Type: Article

References (32)

1. Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol. 2006;62(10):863-870.
2. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194-195.
3. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepres- sants in pregnancy. Am J Obstet Gynecol. 2007;196(6):544-545.
4. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol. 2008;65(4):600-606.
5. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry. 2003;160(5):993-936.
6. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42(3):95-100.
7. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs. 2009;23(6):493-509.
8. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80(1):18-27.
9. Wogelius P, Nørgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006;17(6):701-704.
10. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmaco- epidemiol Drug Saf. 2007;16(10):1075-1085.
11. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antide- pressant medications during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16(10):1086-1094.
12. Kallen BA, Otterblad OP. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79(4):301-308.
13. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a pro- spective controlled multicenter study. JAMA. 1998;279(8):609-610.
14. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106(6):1289-1296.
15. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269(17):2246-2248.
16. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital mal- formations: population based cohort study. BMJ. 2009;339:b3569.
17. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antide- pressant exposure. Am J Psychiatry. 2002;159(12):2055-2061.
18. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confound- ing factors. Clin Ther. 2007;29(5):918-926.
19. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First- trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356(26):2675-2683.
20. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008;83(1):68-76.
21. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluox- etine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66(5):695-705.
22. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356(26):2684-2692.
23. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85(1):11-28.
24. Deave T, Heron J, Evans J, Emond A. The impact of maternal depres- sion in pregnancy on early child development. BJOG. 2008;115(8): 1043-1051.
25. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev. 1995;17(1):165-171.
26. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull. 1998;45(3):320-323.
27. Larsen H, Nielsen GL, Bendsen J, Flint C, Olsen J, Sørensen HT. Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries. Scand J Public Health. 2003;31(1):12-16.
28. Fonager K, Larsen H, Pedersen L, Sørensen HT. Birth outcomes in women exposed to anticonvulsant drugs. Acta Neurol Scand. 2000;101(5):289-294.
29. Nielsen GL, Nørgard B, Puho E, Rothman KJ, Sørensen HT, Czeizel AE. Risk of specific congenital abnormalities in offspring of women with diabetes. Diabet Med. 2005;22(6):693-696.
30. Jepsen B, Jepsen P, Johnsen SP, Espersen GT, Sørensen HT. Validity of diagnoses of cardiac malformations in a Danish population-based hospital-discharge registry. Int J Risk Saf Med. 2006;18(2):77-81.
31. Chambers C. Selective serotonin reuptake inhibitors and congenital malformations. BMJ. 2009;339:b3525.
32. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple- treatments meta-analysis. Lancet. 2009;373(9665):746-758.